{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:54:53Z","timestamp":1785704093186,"version":"3.56.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:35:08Z","timestamp":1781076908000},"page":"485-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma"],"prefix":"10.1016","volume":"26","author":[{"given":"Iemaan","family":"Rana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.06.003_bib0001","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41375-023-01962-5","article-title":"The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms (vol 36, pg 1720, 2022)","volume":"37","author":"Alaggio","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.06.003_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1099265","article-title":"Classification and challenges in the histopathological diagnosis of peripheral T-cell lymphomas, emphasis on the WHO-HAEM5 updates","volume":"12","author":"Murga-Zamalloa","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0003","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-022-01764-1","article-title":"A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas","volume":"37","author":"Falini","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.06.003_bib0004","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood.2023021787","article-title":"New insights into the biology of T-cell lymphomas","volume":"144","author":"Iqbal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0006","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0007","unstructured":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) T-Cell Lymphomas- version 1.20252024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1483."},{"key":"10.1016\/j.clml.2026.06.003_bib0008","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0009","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.06.003_bib0011","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0012","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1200\/JCO.2019.37.15_suppl.7543","article-title":"Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas","volume":"37","author":"Jagadeesh","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0013","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0014","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.16435","article-title":"Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK\/T-cell lymphoma","volume":"189","author":"Huang","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.06.003_bib0015","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood-2024-203577","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma: final results from the phase 2 PRIMO trial","volume":"144","author":"Mehta-Shah","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0016","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2026.06.003_bib0017","first-page":"209","article-title":"Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study","volume":"109","author":"Iyer","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.06.003_bib0018","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1182\/blood-2021-150215","article-title":"A phase Ib study of linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"138","author":"Jin","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0019","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0020","article-title":"A multi-center, real-world study of chidamide for patients with relapsed or refractory peripheral T-cell lymphomas in China","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0021","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1182\/blood-2024-200160","article-title":"Chidamide maintenance therapy for patients with peripheral T-cell lymphoma: a multicenter real-world analysis","volume":"144","author":"Jiang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0022","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic therapies for cancer","volume":"383","author":"Bates","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2026.06.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146657","article-title":"Pivotal phase 2 study of the EZH1 and EZH2 inhibitor valemetostat tosylate (DS-3201b) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"138","author":"Yoshimitsu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0024","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-025-07775-x","article-title":"EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma","volume":"16","author":"Wu","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2026.06.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.7012","article-title":"A phase 1\/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed\/refractory non-Hodgkin lymphoma","volume":"43","author":"Qiu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0027","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01697-z","article-title":"A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and\/or refractory peripheral T-cell lymphoma","volume":"18","author":"Hong","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0028","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study","volume":"11","author":"Dupuis","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.06.003_bib0029","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-134650","article-title":"A phase I\/II study (JACKPOT8) of DZD4205, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0031","article-title":"Golidocitinib in treating refractory or relapsed peripheral T- cell lymphoma: full analysis of the multinational pivotal study results (JACKPOT8)","volume":"142","author":"Song","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0032","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0033","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood-2021-148352","article-title":"Phase 2a study of the dual SYK\/JAK inhibitor Cerdulatinib (ALXN2075) as monotherapy in patients with relapsed\/refractory peripheral TCell lymphoma","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0034","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.06.003_bib0035","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood-2024-206053","article-title":"Results from the first phase 1 clinical study of DR-01, a non-fucosylated anti-CD94 targeting antibody in patients with relapsed\/refractory cytotoxic lymphomas: dose escalation and optimization","volume":"144","author":"Zain","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0036","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2025-777","article-title":"Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia","volume":"146","author":"Marchi","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0037","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2020001966","article-title":"Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas","volume":"4","author":"Neuwelt","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.06.003_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clml.2026.06.003_bib0039","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164793","article-title":"Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment","volume":"8","author":"Gao","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.clml.2026.06.003_bib0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","article-title":"Pseudoprogression and hyperprogression after checkpoint blockade","volume":"58","author":"Wang","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clml.2026.06.003_bib0041","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0042","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9350272","article-title":"Current clinical applications and future perspectives of Immune checkpoint inhibitors in non-Hodgkin lymphoma","volume":"2020","author":"Apostolidis","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.clml.2026.06.003_bib0043","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ajh.27165","article-title":"Aggressive T-cell lymphomas: 2024: updates on diagnosis, risk stratification, and management","volume":"99","author":"Ong","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.06.003_bib0044","article-title":"Author correction: duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nature Med"},{"key":"10.1016\/j.clml.2026.06.003_bib0045","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/bloodadvances.2025016347","article-title":"Real-world evidence of duvelisib and romidepsin in relapsed\/refractory peripheral and cutaneous T-cell lymphomas","volume":"9","author":"Ford","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.06.003_bib0046","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2024-206462","article-title":"Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0047","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.2023023443","article-title":"T-cell lymphoma: the CAR-T revolution is coming","volume":"143","author":"Grover","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0048","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-024-13400-5","article-title":"Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed\/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis","volume":"25","author":"Meng","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2026.06.003_bib0049","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-targeting antibody\u2013drug conjugates for the treatment of T cell cancers","volume":"628","author":"Nichakawade","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.clml.2026.06.003_bib0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","article-title":"TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1\/2 trial","volume":"31","author":"Cwynarski","year":"2025","journal-title":"Nature Med"},{"key":"10.1016\/j.clml.2026.06.003_bib0051","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-190386","article-title":"Senza5 TM CART5: an autologous CD5-deleted anti-CD5 CART product with enhanced anti-T-cell lymphoma activity","volume":"142","author":"Snook","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.003_bib0052","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7086","article-title":"A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed\/refractory T-cell lymphoma (R\/R TCL)","volume":"43","author":"Iyer","year":"2025","journal-title":"J Clinl Oncol"},{"key":"10.1016\/j.clml.2026.06.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-2337","article-title":"A novel CD94-targeting CAR T cell therapy for cytotoxic subtypes of T\/NK-cell malignancies","volume":"146","author":"Le","year":"2025","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:20:36Z","timestamp":1785702036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001771"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}